AJU IB Investment Co. Ltd. Cuts Position in Rapt Therapeutics $RAPT

Key Points

• AJU IB Investment Co. Ltd. significantly reduced its stake in Rapt Therapeutics by 87.5%, now holding only 12,437 shares, representing about 0.1% of its portfolio.
• Several institutional investors increased their positions in Rapt, with Nuveen Asset Management boosting its stake by 50.5% and Invesco Ltd. raising its position by 411.7% during the first quarter.
• Rapt Therapeutics' stock is currently trading at $18.00 with a market capitalization of approximately $297.72 million, while analysts have a consensus price target of $21.57.

AJU IB Investment Co. Ltd. lessened its stake in Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 87.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,437 shares of the company's stock after selling 87,066 shares during the quarter. Rapt Therapeutics makes up 0.1% of AJU IB Investment Co. Ltd.'s holdings, making the stock its 8th biggest position. AJU IB Investment Co. Ltd. owned about 0.08% of Rapt Therapeutics worth $99,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RAPT. Simplicity Wealth LLC bought a new position in Rapt Therapeutics in the 1st quarter worth about $25,000. Invesco Ltd. grew its stake in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock worth $72,000 after acquiring an additional 47,391 shares during the last quarter. Comerica Bank grew its position in shares of Rapt Therapeutics by 53.9% during the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after acquiring an additional 31,287 shares during the period. Callan Family Office LLC lifted its stake in Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock worth $109,000 after purchasing an additional 31,287 shares in the last quarter. Finally, Checkpoint Capital L.P. acquired a new stake in Rapt Therapeutics in the 1st quarter valued at approximately $134,000. 99.09% of the stock is owned by institutional investors and hedge funds.

Rapt Therapeutics Price Performance

Rapt Therapeutics stock traded down $0.64 during trading hours on Friday, reaching $19.86. The stock had a trading volume of 608,248 shares, compared to its average volume of 104,511. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $26.56. The business's 50 day moving average price is $12.31 and its 200-day moving average price is $9.57. The company has a market cap of $328.48 million, a price-to-earnings ratio of -1.40 and a beta of -0.10.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). On average, sell-side analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Analysts Set New Price Targets

RAPT has been the topic of a number of analyst reports. UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the stock a "neutral" rating in a research report on Tuesday, August 12th. Lifesci Capital upgraded shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price objective for the company in a report on Tuesday, July 22nd. Zacks Research downgraded shares of Rapt Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 22nd. Wall Street Zen upgraded Rapt Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and set a $38.00 price objective (down from $51.00) on shares of Rapt Therapeutics in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $21.57.

Rapt Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.